Irinotecan-Kimia

Irinotecan-Kimia
Product Description

  • Inhibits topoisomerase I to interfere with DNA replication and trigger tumor cell apoptosis.
  • Clinically validated through extensive studies in metastatic colorectal and other solid tumors.
  • Delivered via intravenous infusion to integrate seamlessly with established chemotherapy regimens.
  • Demonstrated significant improvements in survival and tumor response across various clinical trials.
  • Supported by a robust body of peer-reviewed research affirming its therapeutic value in oncology.
  • Exhibits a manageable safety profile, with adverse effects that are effectively controlled through clinical oversight.
  • Commonly utilized in combination protocols, including the FOLFIRI regimen, to optimize treatment outcomes.
  • EXAMON Handelsges.m.b.H.

    • AT
    • 2024
      On CPHI since
    Specifications
    • Details
      Concentrate for Solution for Infusion in a single-dose vial for only intravenous infusion after dilution in the following dosage strength: 
      •  100mg/5mL
    • Selling Points
      • Affordability
      • Synergistic treatment utility
      • Premium manufacturing standards
      • Stringent manufacturing quality
      • Value-driven treatment
    • Model
      100mg/5mL

    EXAMON Handelsges.m.b.H.

    • AT
    • 2024
      On CPHI since

    More Products from EXAMON Handelsges.m.b.H. (32)

    • Carboplatin-Kimia

      Product Carboplatin-Kimia

      • Disrupts tumor DNA through crosslink formation to impede cell replication. • Widely validated in the treatment of various solid malignancies, including ovarian and lung cancers. • Administered via infusion to integrate seamlessly into contemporary oncology protocols. • Exhibits manageable adverse eff...
    • Cisplatin-Kimia

      Product Cisplatin-Kimia

      • Facilitates DNA crosslinking to inhibit replication and promote cancer cell apoptosis. • Demonstrates robust efficacy in various solid tumors, including testicular, ovarian, and bladder cancers. • Delivered via infusion, aligning with established oncology treatment protocols. • Often paired with othe...
    • Docetaxel-Kimia

      Product Docetaxel-Kimia

      • A potent taxane agent which stabilizes microtubules to disrupt cell division and promote apoptosis in malignant cells. • Demonstrated efficacy across various cancers including breast, lung, and prostate. • Seamlessly integrated into standard oncology treatment protocols. • Adverse effects are managea...
    • Doxorubicin-Kimia

      Product Doxorubicin-Kimia

      • An anthracycline mechanism which intercalates into DNA and inhibits topoisomerase II, promoting the generation of free radicals that induce tumor cell death. • Demonstrates a longstanding, evidence-based role in treating breast cancer, lymphomas, sarcomas, and other malignancies. • Delivered via IV in...
    • Epirubicin-Kimia

      Product Epirubicin-Kimia

      • An anthracycline derivative which intercalates into DNA and inhibits topoisomerase II, disrupting cancer cell replication. • Demonstrated success in the treatment of breast and other solid tumors through extensive clinical trials. • Delivered via infusion, integrating smoothly into established chemoth...
    • Gemcitabine-Kimia

      Product Gemcitabine-Kimia

      • Gemcitabine functions as a nucleoside analog that, once activated, impedes DNA synthesis and triggers tumor cell death. • Its therapeutic use is well-established in treating a range of malignancies, including pancreatic, lung, and breast cancers. • The drug is administered through intravenous infusion...
    • Methotrexate-Kimia

      Product Methotrexate-Kimia

      • Inhibits dihydrofolate reductase to block folate metabolism and impede DNA synthesis. • Provides rapid therapeutic effects through intravenous, intramuscular, intra-arterial injection. • Widely used in oncology and autoimmune therapies to manage various conditions. • Proven to induce remission a...
    • Oxaliplatin-Kimia

      Product Oxaliplatin-Kimia

      • Platinum-based compound that forms DNA cross-links to disrupt cancer cell replication. • Clinically proven in colorectal and gastrointestinal malignancies through robust trials. • Administered via intravenous infusion, fitting into established chemotherapy regimens such as FOLFOX. • Clinical studies ...
    • Paclitaxel-Kimia

      Product Paclitaxel-Kimia

      • Stabilizes microtubules to obstruct cell division by preventing spindle disassembly. • Supported by extensive clinical evidence in treating breast, ovarian, lung, and other solid tumors. • Administered via intravenous infusion, integrating well with established chemotherapy regimens.
    • Fluorouracil-Kimia

      Product Fluorouracil-Kimia

      • Fluorouracil disrupts DNA synthesis by inhibiting thymidylate synthase, impairing tumor cell proliferation. • Proven efficacy across multiple cancers, including colorectal and breast malignancies, through comprehensive clinical studies. • Primarily administered via intravenous infusion. • Demonstrate...
    • Abiraterone acetate-API

      Product Abiraterone acetate-API

      • High-purity active pharmaceutical ingredient formulated for the production of abiraterone acetate dosage forms. • Effectively inhibits CYP17, contributing to reduced androgen synthesis in prostate cancer therapies. • Presented as a white to off-white crystalline powder that meets strict quality standa...
    • Dasatinib anhydrous/monohydrate-API

      Product Dasatinib anhydrous/monohydrate-API

      • High-purity active pharmaceutical ingredient designed for the manufacture of dasatinib-based formulations. • A potent multi-targeted tyrosine kinase inhibitor effective against BCR-ABL and Src family kinases. • Exhibits robust inhibitory activity, making it a critical component in treatments for CML a...

    Frequently Viewed Together

    Recently Visited